Details for Patent: 9,562,017
Which drugs does patent 9,562,017 protect, and when does it expire?
Patent 9,562,017 protects KOSELUGO and is included in two NDAs.
This patent has thirty-seven patent family members in thirty-one countries.
Summary for Patent: 9,562,017
| Title: | Hydrogen sulfate salt |
| Abstract: | The present invention relates to Compound 1 hydrogen sulfate salt and solvates, crystalline forms and amorphous forms thereof, and to processes for their preparation. |
| Inventor(s): | John DeMattei, Tsung-Hsun Chuang, Gorkhn Sharma-Singh, Paul Alfred Dickinson, Mohammed Pervez, Richard Anthony Storey, Christopher John Squire, James Gair Ford, Ronald John Roberts |
| Assignee: | AstraZeneca R&D Alderley , Alexion Pharma International Operations Ltd , Array Biopharma Inc |
| Application Number: | US14/698,151 |
| Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for patent 9,562,017 |
|
Patent Claim Types: see list of patent claims | Use; Process; Delivery; Dosage form; |
Drugs Protected by US Patent 9,562,017
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Astrazeneca | KOSELUGO | selumetinib sulfate | CAPSULE;ORAL | 213756-001 | Apr 10, 2020 | RX | Yes | No | ⤷ Start Trial | ⤷ Start Trial | Y | TREATMENT OF ADULT AND PEDIATRIC PATIENTS 1 YEAR OF AGE AND OLDER WITH NEUROFIBROMATOSIS TYPE 1 (NF1) WHO HAVE SYMPTOMATIC, INOPERABLE PLEXIFORM NEUROFIBROMAS (PN) | ⤷ Start Trial | |||
| Astrazeneca | KOSELUGO | selumetinib sulfate | CAPSULE;ORAL | 213756-002 | Apr 10, 2020 | RX | Yes | Yes | ⤷ Start Trial | ⤷ Start Trial | Y | TREATMENT OF ADULT AND PEDIATRIC PATIENTS 1 YEAR OF AGE AND OLDER WITH NEUROFIBROMATOSIS TYPE 1 (NF1) WHO HAVE SYMPTOMATIC, INOPERABLE PLEXIFORM NEUROFIBROMAS (PN) | ⤷ Start Trial | |||
| Astrazeneca | KOSELUGO | selumetinib sulfate | GRANULE;ORAL | 219943-001 | Sep 10, 2025 | RX | Yes | Yes | ⤷ Start Trial | ⤷ Start Trial | Y | TREATMENT OF ADULT AND PEDIATRIC PATIENTS 1 YEAR OF AGE AND OLDER WITH NEUROFIBROMATOSIS TYPE 1 (NF1) WHO HAVE SYMPTOMATIC, INOPERABLE PLEXIFORM NEUROFIBROMAS (PN) | ⤷ Start Trial | |||
| Astrazeneca | KOSELUGO | selumetinib sulfate | GRANULE;ORAL | 219943-002 | Sep 10, 2025 | RX | Yes | No | ⤷ Start Trial | ⤷ Start Trial | Y | TREATMENT OF ADULT AND PEDIATRIC PATIENTS 1 YEAR OF AGE AND OLDER WITH NEUROFIBROMATOSIS TYPE 1 (NF1) WHO HAVE SYMPTOMATIC, INOPERABLE PLEXIFORM NEUROFIBROMAS (PN) | ⤷ Start Trial | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
International Family Members for US Patent 9,562,017
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| European Patent Office | 1968948 | ⤷ Start Trial | 301139 | Netherlands | ⤷ Start Trial |
| European Patent Office | 1968948 | ⤷ Start Trial | LUC00234 | Luxembourg | ⤷ Start Trial |
| European Patent Office | 1968948 | ⤷ Start Trial | CA 2021 00044 | Denmark | ⤷ Start Trial |
| European Patent Office | 1968948 | ⤷ Start Trial | PA2021530 | Lithuania | ⤷ Start Trial |
| European Patent Office | 1968948 | ⤷ Start Trial | 2021C/549 | Belgium | ⤷ Start Trial |
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
